# Biotech Daily Digest ‚Äî 2026-01-07

**32 items from 3 sources**

## Summary by Source

- Endpoints News: 8 items
- Fierce Biotech: 9 items
- arXiv q-bio: 15 items


## Endpoints News

- **[Lilly partners with protein mapping startup InduPro for up to $950M](https://endpoints.news/lilly-partners-with-protein-mapping-startup-indupro-for-up-to-950m/)**  
  _Wed, 07 Jan 2026 12:00:37 +0000_  
  Just a month after striking a partnership with Sanofi on an autoimmune disease program, InduPro Therapeutics has landed a second pharma partnership focused on developing cancer drugs with Eli Lilly, the startup told Endpoints News ...

- **[Rakuten Medical raises $100M for photoimmunotherapy platform](https://endpoints.news/rakuten-medical-raises-100m-for-photoimmunotherapy-platform/)**  
  _Wed, 07 Jan 2026 12:00:06 +0000_  
  Rakuten Medical is refueling with $100 million to support an ongoing Phase 3 trial for its photoimmunotherapy.

 The Series F round includes $70 million in new funding and the conversion of $30 million in convertible ...

- **[Cancer biotech Disco lines up Amgen as first pharma partner](https://endpoints.news/cancer-biotech-disco-lines-up-amgen-as-first-pharma-partner/)**  
  _Wed, 07 Jan 2026 10:00:58 +0000_  
  A small German and Swiss biotech working on antibody-drug conjugates and T cell engagers has inked its first big pharma partnership shortly after nabbing a new CEO and seed round extension.

 Amgen will create new ...

- **[J&J plans late-stage trial for lupus candidate after Phase 2 success](https://endpoints.news/jj-plans-late-stage-trial-for-lupus-candidate-after-phase-2-success/)**  
  _Tue, 06 Jan 2026 19:11:01 +0000_  
  Johnson & Johnson‚Äôs monoclonal antibody Imaavy succeeded in a mid-stage lupus trial, bringing the company one step closer to its goal of expanding the drug in other autoimmune diseases.

 Imaavy met its primary endpoint of ...

- **[Bright Minds' shares soar on positive Phase 2 seizure reduction data](https://endpoints.news/bright-minds-shares-soar-on-positive-phase-2-seizure-reduction-data/)**  
  _Tue, 06 Jan 2026 16:33:16 +0000_  
  Bright Minds Biosciences said its selective serotonin receptor agonist succeeded in a mid-stage trial for two different types of seizures, and it plans to take the experimental drug into Phase 3 testing.

 The drug, called ...

- **[Alumis' TYK2 drug succeeds in key psoriasis studies, will seek FDA approval](https://endpoints.news/alumis-tyk2-drug-succeeds-in-key-psoriasis-studies-will-seek-fda-approval/)**  
  _Tue, 06 Jan 2026 16:22:38 +0000_  
  Alumis reported its experimental pill helped clear skin symptoms from psoriasis across two Phase 3 trials, triggering a surge in the Bay Area biotech's stock as it plans to launch into a competitive market with ...

- **[Amgen to acquire Dark Blue Therapeutics for up to $840M](https://endpoints.news/amgen-to-acquire-dark-blue-therapeutics-for-up-to-840m/)**  
  _Tue, 06 Jan 2026 15:49:45 +0000_  
  California biopharma giant Amgen is paying as much as $840 million to boost its oncology pipeline, agreeing to acquire an Oxford University spinout for its lead cancer program.

 UK-based Dark Blue Therapeutics has been an ...

- **[Roche's patent deal with Structure; AstraZeneca reports lupus data](https://endpoints.news/roches-patent-deal-with-structure-astrazeneca-reports-lupus-data/)**  
  _Tue, 06 Jan 2026 14:49:42 +0000_  
  Plus, news about Instil Bio, Gilead and OncoNano, MetaVia, Variant and Boehringer.

 ü§ù Structure Therapeutics reaches licensing deal with Roche: The California biotech granted what‚Äôs known as a ‚Äúfreedom to operate ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/medtech/staar-surgicals-takeover-saga-ends-shareholder-revolt-stops-alcons-attempted-merger-deal" hreflang="en">Staar Surgical's takeover saga ends as shareholder revolt stops Alcon‚Äôs attempted merger deal</a>](https://www.fiercebiotech.com/medtech/staar-surgicals-takeover-saga-ends-shareholder-revolt-stops-alcons-attempted-merger-deal)**  
  _Jan 7, 2026 2:20am_  
  Staar Surgical will remain independent after a bitter shareholder battle that has raged for the past several months has now ended the attempted buyout of the company by Alcon.

- **[<a href="https://www.fiercebiotech.com/biotech/gsks-functional-cure-hep-b-proves-worth-phase-3-trials-setting-approval-push" hreflang="en">GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push</a>](https://www.fiercebiotech.com/biotech/gsks-functional-cure-hep-b-proves-worth-phase-3-trials-setting-approval-push)**  
  _Jan 7, 2026 5:06am_  
  GSK‚Äôs potential ‚Äúfunctional cure‚Äù for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.

- **[<a href="https://www.fiercebiotech.com/biotech/hutchmed-heats-autoimmune-race-phase-3-win-teeing-china-filing" hreflang="en">Hutchmed heats up autoimmune race with phase 3 win, teeing up China filing</a>](https://www.fiercebiotech.com/biotech/hutchmed-heats-autoimmune-race-phase-3-win-teeing-china-filing)**  
  _Jan 7, 2026 4:40am_  
  A phase 3 trial of Hutchmed‚Äôs autoimmune disease candidate sovleplenib has hit its primary endpoint, delivering a boost to an asset that was held up by quality issues in another indication.

- **[<a href="https://www.fiercebiotech.com/medtech/brainspace-garners-fda-clearance-brain-fluid-management-system" hreflang="en">BrainSpace garners FDA clearance for brain fluid management system</a>](https://www.fiercebiotech.com/medtech/brainspace-garners-fda-clearance-brain-fluid-management-system)**  
  _Jan 6, 2026 8:18am_  
  BrainSpace, a medtech focused on neurological injuries and illnesses, received 501(k) clearance from the FDA for its brain fluid management system designed to aid medical staff in providing improved patient care.

- **[<a href="https://www.fiercebiotech.com/biotech/boehringer-continues-kidney-disease-dealmaking-run-120m-variant-bio-pact" hreflang="en">Boehringer continues kidney disease dealmaking run with $120M Variant Bio pact</a>](https://www.fiercebiotech.com/biotech/boehringer-continues-kidney-disease-dealmaking-run-120m-variant-bio-pact)**  
  _Jan 6, 2026 10:03am_  
  Boehringer Ingelheim has unveiled its second kidney-focused collaboration in recent weeks, this time penning a deal worth potentially $120 million with genomics-focused Variant Bio.

- **[<a href="https://www.fiercebiotech.com/biotech/bright-minds-shines-phase-2-win-anti-seizure-serotonin-receptor-activator" hreflang="en">Bright Minds shines with phase 2 win for anti-seizure serotonin receptor activator</a>](https://www.fiercebiotech.com/biotech/bright-minds-shines-phase-2-win-anti-seizure-serotonin-receptor-activator)**  
  _Jan 6, 2026 10:41am_  
  Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech‚Äôs stock a jolt and setting up future registrational trials for the serotonin receptor agonist.

- **[<a href="https://www.fiercebiotech.com/biotech/amgen-stitches-new-acquisition-worth-840m-biotechs-blood-cancer-program" hreflang="en">Amgen stitches new acquisition worth up to $840M for UK biotech and its cancer programs</a>](https://www.fiercebiotech.com/biotech/amgen-stitches-new-acquisition-worth-840m-biotechs-blood-cancer-program)**  
  _Jan 6, 2026 9:47am_  
  Amgen is adding Dark Blue to its tapestry, embedding the U.K. biotech‚Äôs preclinical blood cancer program into its organization.

- **[<a href="https://www.fiercebiotech.com/biotech/roche-shores-100m-keep-its-glp-1-structure-sound" hreflang="en">In Structure licensing deal, Roche commits $100M to shore up GLP-1 position</a>](https://www.fiercebiotech.com/biotech/roche-shores-100m-keep-its-glp-1-structure-sound)**  
  _Jan 6, 2026 9:32am_  
  In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics.

- **[<a href="https://www.fiercebiotech.com/biotech/lilly-returns-nimbus-13b-deal-create-new-oral-obesity-drug" hreflang="en">Lilly returns to Nimbus with $1.3B deal to create new oral obesity drug</a>](https://www.fiercebiotech.com/biotech/lilly-returns-nimbus-13b-deal-create-new-oral-obesity-drug)**  
  _Jan 6, 2026 9:20am_  
  Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot space of oral obesity therapies.


## arXiv q-bio

- **[Constituintes quimicos e atividades biologicas das folhas e cascas do caule de ficus maxima mill. (moraceae)](https://arxiv.org/abs/2601.02420)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02420v1 Announce Type: new 
Abstract: Ficus maxima (Moraceae, subgenus Pharmacosycea), known in Brazil as "caxinguba", occurs in northern Brazil and in Mato Grosso. Its leaves and fruits are important food sources for birds and mammals, and the species is traditionally used by Indigenous peoples of Central‚Ä¶

- **[Apparent Selection Pressure for Channel Capacity in Bacterial Chemotactic Sensors](https://arxiv.org/abs/2601.02446)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02446v1 Announce Type: new 
Abstract: Bacterial chemotactic sensing converts noisy chemical signals into running and tumbling. We analyze the static sensing limits of mixed Tar/Tsr chemoreceptor clusters in individual Escherichia coli cells using a heterogeneous Monod-Wyman-Changeux (MWC) model. By sweeping‚Ä¶

- **[gPC-based robustness analysis of neural systems through probabilistic recurrence metrics](https://arxiv.org/abs/2601.02606)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02606v1 Announce Type: new 
Abstract: Neuronal systems often preserve their characteristic functions and signalling patterns, also referred to as regimes, despite parametric uncertainties and variations. For neural models having uncertain parameters with a known probability distribution, probabilistic robus‚Ä¶

- **[Hierarchical temporal receptive windows and zero-shot timescale generalization in biologically constrained scale-invariant deep networks](https://arxiv.org/abs/2601.02618)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02618v1 Announce Type: new 
Abstract: Human cognition integrates information across nested timescales. While the cortex exhibits hierarchical Temporal Receptive Windows (TRWs), local circuits often display heterogeneous time constants. To reconcile this, we trained biologically constrained deep networks, ba‚Ä¶

- **[DNACHUNKER: Learnable Tokenization for DNA Language Models](https://arxiv.org/abs/2601.03019)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03019v1 Announce Type: new 
Abstract: DNA language models have emerged as powerful tools for decoding the complex language of DNA sequences. However, the performance of these models is heavily affected by their tokenization strategy, i.e., a method used to parse DNA sequences into a shorter sequence of chun‚Ä¶

- **[Transformers self-organize like newborn visual systems when trained in prenatal worlds](https://arxiv.org/abs/2601.03117)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.03117v1 Announce Type: new 
Abstract: Do transformers learn like brains? A key challenge in addressing this question is that transformers and brains are trained on fundamentally different data. Brains are initially "trained" on prenatal sensory experiences (e.g., retinal waves), whereas transformers are typ‚Ä¶

- **[Effect of Electric Charge on Biotherapeutic Transport, Binding and Absorption: A Computational Study](https://arxiv.org/abs/2601.00505)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.00505v1 Announce Type: cross 
Abstract: This study explores the effects of electric charge on the dynamics of drug transport and absorption in subcutaneous injections of monoclonal antibodies (mAbs). We develop a novel mathematical and computational model, based on the Nernst-Planck equations and porous med‚Ä¶

- **[Multi-scale Graph Autoregressive Modeling: Molecular Property Prediction via Next Token Prediction](https://arxiv.org/abs/2601.02530)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02530v1 Announce Type: cross 
Abstract: We present Connection-Aware Motif Sequencing (CamS), a graph-to-sequence representation that enables decoder-only Transformers to learn molecular graphs via standard next-token prediction (NTP). For molecular property prediction, SMILES-based NTP scales well but lacks‚Ä¶

- **[Credit Assignment via Neural Manifold Noise Correlation](https://arxiv.org/abs/2601.02636)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02636v1 Announce Type: cross 
Abstract: Credit assignment--how changes in individual neurons and synapses affect a network's output--is central to learning in brains and machines. Noise correlation, which estimates gradients by correlating perturbations of activity with changes in output, provides a biologi‚Ä¶

- **[Simple chemical systems with chaos](https://arxiv.org/abs/2601.02787)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02787v1 Announce Type: cross 
Abstract: A number of simple chaotic three-dimensional dynamical systems (DSs) with quadratic polynomials on the right-hand sides are reported in the literature, containing exactly 5 or 6 monomials of which only 1 or 2 are quadratic. However, none of these simple systems are ch‚Ä¶

- **[A Mathematical Formalization of Self-Determining Agency](https://arxiv.org/abs/2601.02885)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2601.02885v1 Announce Type: cross 
Abstract: Defining agency is an extremely important challenge for cognitive science and artificial intelligence. Physics generally describes mechanical happenings, but there remains an unbridgeable gap between them and the acts of agents. To discuss the morality and responsibil‚Ä¶

- **[Exploring Multi-Objective Trade-offs in Reference Compound Selection for Validation Studies of Toxicity Assays](https://arxiv.org/abs/2505.07140)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2505.07140v2 Announce Type: replace 
Abstract: Validation studies that assess the applicability and reliability of analytical and predictive methods rely on reference sets whose composition implicitly encodes multiple competing design objectives. Because these trade-offs are typically addressed through expert ju‚Ä¶

- **[Integrating upstream and downstream reciprocity stabilizes cooperator-defector coexistence in others-only public goods games](https://arxiv.org/abs/2509.04743)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2509.04743v2 Announce Type: replace 
Abstract: Human cooperation persists among strangers in large, well-mixed populations despite theoretical predictions of difficulties, leaving a fundamental evolutionary puzzle. While upstream (pay-it-forward: helping others because you were helped) and downstream (rewarding-‚Ä¶

- **[Neural Receptive Fields, Stimulus Space Embedding and Effective Geometry of Scale-Free Networks](https://arxiv.org/abs/2509.25453)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2509.25453v2 Announce Type: replace 
Abstract: Understanding how receptive fields emerge and organize within brain networks and how neural dynamics couple with stimuli space is fundamental to neuroscience. Models often rely on fine-tuning connectivity to match empirical data, which may limit biological plausibil‚Ä¶

- **[Scalable Scientific Interest Profiling Using Large Language Models](https://arxiv.org/abs/2508.15834)**  
  _Wed, 07 Jan 2026 00:00:00 -0500_  
  arXiv:2508.15834v2 Announce Type: replace-cross 
Abstract: Research profiles highlight scientists' research focus, enabling talent discovery and collaborations, but are often outdated. Automated, scalable methods are urgently needed to keep profiles current. We design and evaluate two Large Language Models (LLMs)-base‚Ä¶
